Interleukin-1 receptor-1-deficientmiceshowattenuated production of ocular surface inflammatory cytokines in experimental dry eye

Cornea

Volumn 27, Issue 7, 2008, Pages 811-817

  Narayanan, Srihari ^a,b   Corrales, Rosa M ^c,d   Farley, William ^c   McDermott, Alison M ^b   Pflugfelder, Stephen C ^c  

^a PENNSYLVANIA COLLEGE OF OPTOMETRY   (United States)

^b UNIVERSITY OF HOUSTON   (United States)

^c CULLEN EYE INSTITUTE   (United States)

^d BIOMATERIALES Y NANOMEDICINA CIBER BBN   (Spain)

Author keywords

Cytokines; Defensins; Dry eye disease; Inflammation; Mice

Indexed keywords

BETA DEFENSIN 2; BETA DEFENSIN 3; COMPLEMENTARY DNA; GAMMA INTERFERON; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; MESSENGER RNA; SCOPOLAMINE; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE; DEFENSIN; EYE PROTEIN; INTERLEUKIN 1 RECEPTOR TYPE I; TEAR PROTEINS;

ANIMAL EXPERIMENT; ARTICLE; CONCENTRATION (PARAMETERS); CONJUNCTIVA EPITHELIUM; CONTROLLED STUDY; CORNEA EPITHELIUM; CYTOKINE PRODUCTION; DRY EYE; ENZYME IMMUNOASSAY; HUMIDITY; INFLAMMATION; LACRIMAL FLUID; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA EXTRACTION; RNA TRANSCRIPTION; ANIMAL; C57BL MOUSE; CONJUNCTIVA DISEASE; CORNEA DISEASE; DISEASE MODEL; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOUSE MUTANT; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; CONJUNCTIVAL DISEASES; CORNEAL DISEASES; CYTOKINES; DEFENSINS; DISEASE MODELS, ANIMAL; DRY EYE SYNDROMES; ENZYME-LINKED IMMUNOSORBENT ASSAY; EYE PROTEINS; GENE EXPRESSION REGULATION; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RECEPTORS, INTERLEUKIN-1 TYPE I; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TEARS;

EID: 49849088020     PISSN: 02773740     EISSN: None     Source Type: Journal    
DOI: 10.1097/ICO.0b013e31816bf46c     Document Type: Article

References (41)

1. Lemp MA. Report of the National Eye Institute/Industry workshop on Clinical Trials in Dry Eyes. CLAO J. 1995;21:221-232.
2. Perry HD, Donnenfeld ED. Dry eye diagnosis and management in 2004. Curr Opin Ophthalmol. 2004;15:299-304.
3. Stern ME, Gao J, Siemasko KF, et al. The role of the lacrimal functional unit in the pathophysiology of dry eye. Exp Eye Res. 2004;78:409-416.
4. Pflugfelder SC, Solomon A, Stern ME. The diagnosis and management of dry eye: a twenty-five-year review. Cornea. 2000;19:644-649.
5. Pflugfelder SC. Antiinflammatory therapy for dry eye. Am J Ophthalmol. 2004;137:337-342.
6. Barton K, Monroy DC, Nava A, et al. Inflammatory cytokines in the tears of patients with ocular rosacea. Ophthalmology. 1997;104:1868-1874.
7. Afonso AA, Sobrin L, Monroy DC, et al. Tear fluid gelatinase B activity correlates with IL-1alpha concentration and fluorescein clearance in ocular rosacea. Invest Ophthalmol Vis Sci. 1999;40:2506-2512.
8. Solomon A, Dursun D, Liu Z, et al. Pro- and anti-inflammatory forms of interleukin-1 in the tear fluid and conjunctiva of patients with dry-eye disease. Invest Ophthalmol Vis Sci. 2001;42:2283-2292.
9. Jones DT, Monroy D, Ji Z, et al. Alterations of ocular surface gene expression in Sjogren's syndrome. Adv Exp Med Biol. 1998;438:533-536.
10. Narayanan S, Miller WL, McDermott AM. Expression of human b-defensins in conjunctival epithelium: relevance to dry eye disease. Invest Ophthalmol Vis Sci. 2003;44:3795-3801.
11. McDermott AM, Redfern RL, Zhang B, et al. Defensin expression by the cornea: multiple signalling pathways mediate IL-1beta stimulation of hBD-2 expression by human corneal epithelial cells. Invest Ophthalmol Vis Sci. 2003;44:1859-1865.
12. Marsh P, Pflugfelder SC. Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjogren syndrome. Ophthalmology. 1999;106:811-816.
13. Gunduz K, Ozdemir O. Topical cyclosporin treatment of keratoconjunctivitis sicca in secondary Sjogren's syndrome. Acta Ophthalmol (Copenh). 1994;72:438-442.
14. Pflugfelder SC, Maskin SL, Anderson B, et al. A randomized, doublemasked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance. Am J Ophthalmol. 2004;138:444-457.
15. Stevenson D, Tauber J, Reis BL. Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The Cyclosporin A Phase 2 Study Group. Ophthalmology. 2000;107:967-974.
16. Brignole F, Pisella PJ, De Saint Jean M, et al. Flow cytometric analysis of inflammatory markers in KCS: 6-month treatment with topical cyclosporin A. Invest Ophthalmol Vis Sci. 2001;42:90-95.
17. Labow M, Shuster D, Zetterstrom M, et al. Absence of IL-1 signaling and reduced inflammatory response in IL-1 type I receptor-deficient mice. J Immunol. 1997;159:2452-2461.
18. Horai R, Asano M, Sudo K, et al. Production of mice deficient in genes for interleukin (IL)-1alpha, IL-1beta, IL-1alpha/beta, and IL-1 receptor antagonist shows that IL-1beta is crucial in turpentine-induced fever development and glucocorticoid secretion. J Exp Med. 1998;187:1463-1475.
19. Zheng H, Fletcher D, Kozak W, et al. Resistance to fever induction and impaired acute-phase response in interleukin-1 beta-deficient mice. Immunity. 1995;3:9-19.
20. Rosenbaum JT, Han YB, Park JM, et al. Tumor necrosis factor-alpha is not essential in endotoxin induced eye inflammation: studies in cytokine receptor deficient mice. J Rheumatol. 1998;25:2408-2416.
21. Yeh S, Song XJ, Farley W, et al. Apoptosis of ocular surface cells in experimentally induced dry eye. Invest Ophthalmol Vis Sci. 2003;44:124-129.
22. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987;162:156-159.
23. Corrales RM, Calonge M, Herreras JM, et al. Levels of mucin gene expression in normal human conjunctival epithelium in vivo. Curr Eye Res. 2003;27:323-328.
24. Dursun D, Wang M, Monroy D, et al. A mouse model of keratoconjunctivitis sicca. Invest Ophthalmol Vis Sci. 2002;43:632-638.
25. Corrales RM, Stern ME, De Paiva CS, et al. Desiccating stress stimulates expression of matrix metalloproteinases by the corneal epithelium. Invest Ophthalmol Vis Sci. 2006;47:3293-3302.
26. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood. 1996;87: 2095-2147.
27. Dinarello CA. Interleukin-1. In: Thomson A, ed. The Cytokine Handbook. San Diego: Academic Press; 1998:35-72.
28. Josephs MD, Solorzano CC, Taylor M, et al. Modulation of the acute phase response by altered expression of the IL-1 type 1 receptor or IL-1ra. Am J Physiol Regul Integr Comp Physiol. 2000;278:R824-R830.
29. Dinarello CA. Interleukin-1 family [IL-1F1, F2]. In: Thomson A, Lotze MT, eds. The Cytokine Handbook. San Diego: Academic Press; 2003:3-18.
30. Dursun D, Wang M, Monroy D, et al. Experimentally induced dry eye produces ocular surface inflammation and epithelial disease. Adv Exp Med Biol. 2002;506:647-655.
31. Narayanan S, Glasser A, Hu Y-S, et al. The effect of interleukin-1 on cytokine gene expression by human corneal epithelial cells. Exp Eye Res. 2005;80:175-183.
32. Nakamura Y, Sotozono C, Kinoshita S. Inflammatory cytokines in normal human tears. Curr Eye Res. 1998;17:673-676.
33. Boraschi D, Tagliabue A. The interleukin-1 receptor family. Vitam Horm. 2006;74:229-254.
34. Jorres A, Bender TO, Finn A, et al. Biocompatibility and buffers: effect of bicarbonate-buffered peritoneal dialysis fluids on peritoneal cell function. Kidney Int. 1998;54:2184-2193.
35. Vanden BergheW, Vermeulen L, DeWilde G, et al. Signal transduction by tumor necrosis factor and gene regulation of the inflammatory cytokine interleukin-6. Biochem Pharmacol. 2000;60:1185-1195.
36. Patil AA, Cai Y, Sang Y, et al. Cross-species analysis of the mammalian beta-defensin gene family: presence of syntenic gene clusters and preferential expression in the male reproductive tract. Physiol Genomics. 2005;23:5-17.
37. Schofield DA, Westwater C, Balish E. beta-defensin expression in immunocompetent and immunodeficient germ-free and Candida albicansmonoassociated mice. J Infect Dis. 2004;190:1327-1334.
38. Biragyn A, Ruffini PA, Leifer CA, et al. Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2. Science. 2002;298:1025-1029.
39. Bals R, Wang X, Meegalla RL, et al. Mouse beta-defensin 3 is an inducible antimicrobial peptide expressed in the epithelia of multiple organs. Infect Immun. 1999;67:3542-3547.
40. Raj PA, Dentino AR. Current status of defensins and their role in innate and adaptive immunity. FEMS Microbiol Lett. 2002;206:9-18.
41. Kinoshita S, Adachi W, Sotozono C, et al. Characteristics of the human ocular surface epithelium. Prog Retin Eye Res. 2001;20:639-673.